Lipocine Inc. (LPCN) News
Filter LPCN News Items
LPCN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest LPCN News From Around the Web
Below are the latest news stories about LIPOCINE INC that investors may wish to consider to help them evaluate LPCN as an investment opportunity.
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of its Phase 2 study evaluating LPCN 1148 are being presented at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, taking place in Boston MA. The results are featured in a late-breaking oral presentation and e-poster by Dr. Arun Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic He |
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the third quarter and nine months ended September 30, 2023, and provided a corporate update. |
Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that an abstract on LPCN 1148 has been selected for a late breaking oral presentation at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, to take place in Boston MA, November 10 to 14, 2023. |
Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum DepressionLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform, today announced the completion of a meeting with the FDA and guidance for the appropriate acceptance criteria for the upcoming LPCN 1154 pivotal study. |
Lipocine to Present at the H.C. Wainwright Annual NASH Investor ConferenceLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will present and meet with investors at the H.C. Wainwright 7th Annual NASH Investor Conference, taking place virtually October 24, 2023. |
Lipocine to Present at the Cantor Fitzgerald Global Healthcare ConferenceLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh Patel, President and Chief Executive Officer, will present and meet with investors at the 2023 Cantor Fitzgerald Global Healthcare Conference to take place September 26th to September 28th in New York City. |
LPCN: Trial Results Improve OutlookBy John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 2Q:23 Financial and Operational Results Two clinical trial readouts dominated Lipocine Inc.’s (NASDAQ:LPCN) news flow year to date: The pharmacokinetic (PK) study for LPCN 1154, which is in development for postpartum depression (PPD) and topline results from the Phase II study for LPCN 1148 in adult men with cirrhosis of the |
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced financial results for the second quarter and six months ended June 30, 2023, and provided a corporate update. |
LPCN: 1148 Shows Muscle Loss ReversalBy John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Lipocine Inc. (NASDAQ:LPCN) provided a pleasant surprise to investors with its strong Phase II results from its LPCN 1148 study as presented in a July 27th press release . A slide presentation was concurrently provided which can be accessed here . A The study was intended to measure the efficacy, safety and tolerability of |
Why Is Lipocine (LPCN) Stock Up 32% Today?Lipocine (LPCN) stock is rising higher on Thursday after the company released positive results from a Phase 2 clinical trial. |